On May 22, 2019 Personalis, Inc., a leader in advanced genomics for cancer, reported that the Parker Institute for Cancer Immunotherapy will utilize Personalis’ cancer immunogenomics platform, ImmunoID NeXT, for the investigation of biomarkers of response to immunotherapies in clinical trial participants (Press release, Personalis, MAY 22, 2019, View Source [SID1234536523]). The trials include melanoma, pancreatic, and all-comer solid tumor patients treated with checkpoint inhibitors, either as monotherapy or in combination with other cancer therapeutics. This project builds on Personalis’ existing relationship with the Parker Institute as a contributing industry member of the TESLA Consortium, which focuses on improving neoantigen prediction algorithms.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Unlike traditional biomarker interrogation approaches that require several individual assays, which may be costly and time-consuming, and which may exhaust limited tumor tissue sample, ImmunoID NeXT consolidates multiple biomarker assays into one, meaning researchers no longer need to make the difficult choice regarding which biomarkers to analyze. The platform represents an end-to-end solution for immuno and precision oncology biomarker discovery applications, simultaneously enabling the analysis of: tumor mutations, neoantigens, immune repertoire clonality, tumor escape mechanisms (including HLA-related somatic mutations and genotyping), tumor mutational burden (TMB), microsatellite instability (MSI), oncoviruses, and more.
"Personalis’ platform could help us better understand which patients will respond or not respond to immunotherapy and why," said Theresa LaVallee, PhD, VP Translational Medicine and Regulatory Affairs at the Parker Institute.
"We’re excited to work with the Parker Institute on this important new project," said Dr. Richard Chen, MD, Personalis’ Chief Scientific Officer. "Both organizations are focused on improving outcomes for cancer patients, and we believe that ImmunoID NeXT is the catalyst that our partners and customers can leverage to discover more effective biomarkers of response to immunotherapies."